Format

Send to

Choose Destination
Cancers (Basel). 2018 Oct 31;10(11). pii: E413. doi: 10.3390/cancers10110413.

Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer.

Wu PY1, Lin YC2, Huang YL3,4, Chen WM5, Chen CC6,7, Lee H8,9,10,11.

Author information

1
Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan. d96b41003@ntu.edu.tw.
2
Department of Life Sciences, National Taiwan University, Taipei 10617, Taiwan. d01b41001@ntu.edu.tw.
3
Department of Biotechnology, Asia University, Taichung 41354, Taiwan. yuanli@asia.edu.tw.
4
Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan. yuanli@asia.edu.tw.
5
Department of Life Sciences, National Taiwan University, Taipei 10617, Taiwan. f03b21010@ntu.edu.tw.
6
Department of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan. 07265@cych.org.tw.
7
Department of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan 71710, Taiwan. 07265@cych.org.tw.
8
Department of Life Sciences, National Taiwan University, Taipei 10617, Taiwan. hsinyu@ntu.edu.tw.
9
Department of Electrical Engineering, National Taiwan University, Taipei 10617, Taiwan. hsinyu@ntu.edu.tw.
10
Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei 10617, Taiwan. hsinyu@ntu.edu.tw.
11
Center for Biotechnology, National Taiwan University, Taipei 10617, Taiwan. hsinyu@ntu.edu.tw.

Abstract

Prostate cancer (PCa) is the most common noncutaneous cancer in men worldwide. One of its major treatments is androgen deprivation therapy, but PCa frequently relapses as aggressive castration resistant local tumors and distal metastases. Hence, the development of novel agents or treatment modalities for advanced PCa is crucial. Many tumors, including PCa, first metastasize to regional lymph nodes via lymphatic vessels. Recent findings demonstrate that the bioactive lipid lysophosphatidic acid (LPA) promotes PCa progression by regulating vascular endothelial growth factor-C (VEGF-C), a critical mediator of tumor lymphangiogenesis and lymphatic metastasis. Many of the underlying molecular mechanisms of the LPA⁻VEGF-C axis have been described, revealing potential biomarkers and therapeutic targets that may aid in the diagnosis and treatment of advanced PCa. Herein, we review the literature that illustrates a functional role for LPA signaling in PCa progression. These discoveries may be especially applicable to anti-lymphangiogenic strategies for the prevention and therapy of metastatic PCa.

KEYWORDS:

LPA; LPA receptor; VEGF-C; lymphangiogenesis; prostate cancer

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center